Goldline Pharmaceutical Files IPO Papers with BSE SME; Fresh Issue of 30 Lakh Shares

Nagpur, October 3: Goldline Pharmaceutical Limited has announced that it has filed its draft red herring prospectus with the Securities and Exchange Board of India (SEBI). The IPO issue will be an entirely fresh issue of 30,00,000 equity shares, with no offer for sale element.

Goldline Pharmaceutical Limited is an Indian pharmaceutical company. It specialises in the trade and marketing of generic pharmaceutical drugs in India. The company was established in 2004, and is headquartered in Nagpur, Maharashtra. The company markets pharmaceutical products under its brand named ‘Goldline’.

Goldline Pharmaceutical IPO Listing Proposed on BSE SME

The 100% book build issue of Goldline Pharmaceutical Limited is proposed to be listed on BSE SME. However, the company is yet to announce the key details of the IPO, such as the issue size, price band, and lot size. The promoters of the company are Amol Laxmikant Mujumdar, and Swapan Premprakash Khandelwal. Cumulative Capital Pvt Ltd is the book running lead manager, while Bigshare Services Pvt Ltd is the registrar of the issue.

Goldline Pharmaceutical IPO Revenue At ₹2,805.57 Lakh While PAT At ₹283.42 Lakh

In FY25, the company’s revenue from operations stood at ₹2,805.57 lakh (vs. ₹2,356.60 lakh in FY24), profit after tax at ₹283.42 lakh (vs. ₹180.60 lakh in FY24), EBITDA margin at 20.8% in FY25 (improved from 18.3% in FY24). Furthermore, EPS (FY25) was ₹4.11 per share, Net Worth (FY25) was ₹1,035.34 lakh, Return on Net Worth (FY25) was 27.38%, and NAV per share (FY25) was ₹12.39.

Goldline Pharmaceutical  IPO Prepayment and Repayment Main Fundraising Motive

The company will utilise ₹890 lakh for prepayment and repayment of certain borrowings, while the balance amount will be utilised for general corporate purposes.

Goldline Pharmaceutical’s proposed SME IPO will help in reducing debt. It will also support the company in expanding its market share in the pharma sector. With a positive financial performance, investors will be waiting to know the key details about the IPO.

REF: https://www.bsesme.com/download/337239/SME_IPO InPrinciple/DRHP_Goldline_Pharmaceutical_Limited_20250930225851.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations